Characterization of Gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretome
about
Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cellsA Review of Gaucher Disease Pathophysiology, Clinical Presentation and TreatmentsInternational Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials.Unexpected macrophage-independent dyserythropoiesis in Gaucher disease.Long-term response in biochemical markers of bone turnover during enzyme replacement therapy in a case-series of patients with Gaucher disease type I from Northern Greece.Vertebral fractures in Gaucher disease type I: data from the French "Observatoire" on Gaucher disease (FROG).MMP9 integrates multiple immunoregulatory pathways that discriminate high suppressive activity of human mesenchymal stem cells.Expanding spectrum of the association between Type 1 Gaucher disease and cancers: a series of patients with up to 3 sequential cancers of multiple types--correlation with genotype and phenotype.Mesenchymal stem cells as cellular vectors for pediatric neurological disordersCommon and uncommon pathogenic cascades in lysosomal storage diseasesSkeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat.Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage.Gaucher's disease and cancer: a sphingolipid perspectiveA prospective study of bone marrow hematopoietic and mesenchymal stem cells in type 1 Gaucher disease patientsWhole genome expression in peripheral-blood samples of workers professionally exposed to polycyclic aromatic hydrocarbons.The influence of genetic variability and proinflammatory status on the development of bone disease in patients with Gaucher disease.Immunological cell type characterization and Th1-Th17 cytokine production in a mouse model of Gaucher disease.Bone turnover markers in patients with type 1 Gaucher disease.Sphingolipids: the nexus between Gaucher disease and insulin resistance.The pathophysiology of GD - current understanding and rationale for existing and emerging therapeutic approaches.Gaucher disease and cancer: concept and controversy.FMNL2 is a positive regulator of cell motility and metastasis in colorectal carcinoma.Coenzyme Q10 partially restores pathological alterations in a macrophage model of Gaucher disease.Expression of CHI3L1 and CHIT1 in osteoarthritic rat cartilage model. A morphological study.Evaluation of bone involvement in patients with Gaucher disease: a semi-quantitative magnetic resonance imaging method (using ROI estimation of bone lesion) as an alternative method to semi-quantitative methods used so far.Effect of glycosphingolipids on osteoclastogenesis and osteolytic bone diseases.Osteopontin polymorphic susceptibility factor for Parkinson's disease among patients with Gaucher disease.Cerebrospinal fluid fatty acids in glucocerebrosidase-associated Parkinson's disease.Risk factors for fractures and avascular osteonecrosis in type 1 Gaucher disease: a study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry.Fra-2 Expression in Osteoblasts Regulates Systemic Inflammation and Lung Injury through Osteopontin
P2860
Q28308084-673C9BF7-C942-4F90-8BD5-03BE004DCDA7Q30235844-71E3A107-97ED-43CB-ADAA-376F2ED51A27Q30488740-D386DD44-42D5-47AC-B761-0CC86A7EFBEDQ33434241-6A0B9F53-95BF-4C9B-B89F-76F6CE74DD62Q33554559-C2EC86BB-0DD8-4E00-81E0-B5516E190C3CQ33648876-25CB9801-5D5D-464B-984E-3A6C3700450CQ33678477-6B260176-DB09-4AEE-B34D-C729B354737CQ33874873-B37FA30F-C7A5-4A2C-85FB-BFD65E32DEA2Q33918923-01E633D5-A7AC-41A7-A568-0F74C217AB38Q33966917-476BEC16-3AB4-454F-B60C-F700237A6485Q34079226-E085C5BB-EE99-47B2-ABD1-6BA078D7D240Q34320470-DDA66337-AEBC-40B5-A453-612C50A7A4F9Q34333982-77E71E67-3DDB-44F1-A7BA-DC42B5784082Q34919711-3B42DC58-2142-45BE-B4A9-F2800ABD63A0Q35532105-4AC82B2B-01F4-4B4A-BF47-03EAD302F92FQ35611123-5555921E-633D-47E9-B070-0C487284EF35Q36055464-47B13744-0215-4FF6-9CE4-D8781CFECE92Q36562916-6AA4F778-FD77-4A32-8E4F-AF1E1C8D86C0Q37799400-BB413715-B420-4026-BD9A-F29BF9AF1F60Q37827416-7D350917-75FF-4119-9968-C5DD5CC7D6F3Q37901381-F0C101C6-D2C2-4D77-86BC-63B020944226Q38502636-E7C9D03F-BE2D-403A-824F-DC44107213AAQ38976036-35B38358-3EA2-43BF-B948-0136902C0FB3Q39114446-813CDEAD-BE8F-47E3-8265-70FAA1550E9CQ41489523-1F0E6AF4-8E0B-4FD1-BD0F-25C1D101EE14Q42288514-AEB3854D-633C-430A-AF97-676CE32ADE70Q43792274-3E8F590C-80B4-4F0D-89E4-73FD0AF5D96AQ48824358-8BF02BF8-EEA4-4452-B81D-3DAD65410F7EQ53128627-16866ED8-74F9-4B28-A12D-E34D9173E1EDQ58326827-79DC6D3C-3EA7-4C59-9A28-9BED7BCC3FBB
P2860
Characterization of Gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretome
description
2009 nî lūn-bûn
@nan
2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Characterization of Gaucher di ...... altered inflammatory secretome
@ast
Characterization of Gaucher di ...... altered inflammatory secretome
@en
type
label
Characterization of Gaucher di ...... altered inflammatory secretome
@ast
Characterization of Gaucher di ...... altered inflammatory secretome
@en
prefLabel
Characterization of Gaucher di ...... altered inflammatory secretome
@ast
Characterization of Gaucher di ...... altered inflammatory secretome
@en
P2093
P2860
P1433
P1476
Characterization of Gaucher di ...... altered inflammatory secretome
@en
P2093
Gregory A Grabowski
Jacques Galipeau
Marie-Noëlle Boivin
Moutih Rafei
Philippe M Campeau
P2860
P304
P356
10.1182/BLOOD-2009-02-205708
P407
P577
2009-07-08T00:00:00Z